These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 32843722

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen.
    Hurtado A, Holmes KA, Geistlinger TR, Hutcheson IR, Nicholson RI, Brown M, Jiang J, Howat WJ, Ali S, Carroll JS.
    Nature; 2008 Dec 04; 456(7222):663-6. PubMed ID: 19005469
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression.
    Giordano C, Catalano S, Panza S, Vizza D, Barone I, Bonofiglio D, Gelsomino L, Rizza P, Fuqua SA, Andò S.
    Oncogene; 2011 Sep 29; 30(39):4129-40. PubMed ID: 21499302
    [Abstract] [Full Text] [Related]

  • 6. Loss of B-cell translocation gene 2 expression in estrogen receptor-positive breast cancer predicts tamoxifen resistance.
    Takahashi M, Hayashida T, Okazaki H, Miyao K, Jinno H, Kitagawa Y.
    Cancer Sci; 2014 Jun 29; 105(6):675-82. PubMed ID: 24698107
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. LncRNA LINP1 confers tamoxifen resistance and negatively regulated by ER signaling in breast cancer.
    Ma T, Liang Y, Li Y, Song X, Zhang N, Li X, Chen B, Zhao W, Wang L, Yang Q.
    Cell Signal; 2020 Apr 29; 68():109536. PubMed ID: 31927036
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. EPRS is a critical regulator of cell proliferation and estrogen signaling in ER+ breast cancer.
    Katsyv I, Wang M, Song WM, Zhou X, Zhao Y, Park S, Zhu J, Zhang B, Irie HY.
    Oncotarget; 2016 Oct 25; 7(43):69592-69605. PubMed ID: 27612429
    [Abstract] [Full Text] [Related]

  • 15. ERRγ target genes are poor prognostic factors in Tamoxifen-treated breast cancer.
    Madhavan S, Gusev Y, Singh S, Riggins RB.
    J Exp Clin Cancer Res; 2015 May 15; 34(1):45. PubMed ID: 25971350
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.
    Bhatt S, Stender JD, Joshi S, Wu G, Katzenellenbogen BS.
    Oncogene; 2016 Nov 03; 35(44):5722-5734. PubMed ID: 27065334
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.